Cancer cachexia drug, TCMCB07, will start an innovative Phase 2
trial in 2025
Cachexia is a metabolic syndrome characterized by an uncontrollable loss in body mass. It is a common comorbidity for patients with cancer and other chronic conditions.
Cachexia decreases patient quality of life by causing debilitating fatigue, weakness, and reduced mobility.
50% of diagnosed cancer patients are affected by cachexia each year.1
Up to 30% of deaths in late-stage cancer patients are caused by cachexia.2
There are currently no clinically-approved, efficacious
drugs treating cachexia in the United States.2 Endevica is changing that.
Treatment that’s proactive, not reactive3
This is an innovative, prophylactic treatment paradigm aimed at improving health outcomes and obviating the traditional approach being used by competitors.
Traditional Treatment Approach
- Cachexia is treated upon diagnosis in a reactive manner. After patients regain weight, they are taken off treatment and lose weight again.
- Patient suffers clinical harm from suboptimal approach.
Prophylactic Treatment Approach
- Cachexia is prevented with adjuvant treatment in newly-diagnosed cancer patients, maintaining a healthy body weight before extensive mass loss has occurred.4
- By treating newly-diagnosed cancer patients, the weight gain caused by TCMCB07 could improve patients’ outcomes.5
Advantages of TCMCB07
Poised for Growth, Clear Milestones Ahead
Phase 2 innovative trial begins
Phase 2 traditional trial begins
Phase 3 pivotal trial begins
1. Mariean et al. Cancers. 2023.
2. Cleveland Clinic. (n.d.). Cancer cachexia. https://my.clevelandclinic.org/health/diseases/cancer-cachexia
3. https://www.biospace.com/press-releases/endevica-bio-to-start-phase-2-clinical-trial-of-drug-to-prevent-weight-loss-in-cancer-patients
4. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e15195
5. Lennon et al. Curr Oncol Rep. 2016. and Zadeh et al. JCSM. 2013.